Starry Sea Acquisition Corp (SSEA) · Oct 9, 2026 · Other events
Meeting postponed — October 19 meeting; 1.468M public shares remain after 4.282M redemptions
Starry Sea Acquisition postponed its meeting to October 19 after 4.28 million shares sought redemption, complicating its extension vote.
Starry Sea is a SPAC trying to complete its proposed combination with SuperiorMed, a healthcare-management business, while extending its deadline to find or close a transaction. The October 9 filing does not advance the deal itself; it shows the vote is becoming harder to execute.
The shareholder vote has been pushed back, signaling unresolved support. SSEA postponed the extraordinary meeting from October 9 to October 19 to continue engaging shareholders. 〔0〕 The direction was already known because the postponement had been announced separately, so the filing mainly confirms that the company still lacks enough certainty to proceed on the original timetable.
Redemptions are the sharper problem: most public shares have asked to leave. Of the public shares subject to redemption, 4,281,993 were submitted, leaving only 1,468,007 outstanding. 〔1〕 SSEA is seeking reversals on roughly 350,174 shares, which would lift the remaining count to at least 1,818,181. 〔2〕
| Filing metric | Amount | Comparison / implication |
|---|---|---|
| Public shares submitted for redemption | 4,281,993 | Leaves a substantially smaller public float (Redemption tabulation) |
| Public shares remaining | 1,468,007 | Before sought redemption reversals (Redemption tabulation) |
| Shares targeted for redemption reversals | ~350,174 | Would raise remaining shares to at least 1,818,181 (Redemption tabulation) |
| Estimated monthly extension contribution | ~$59,999.97 | Based on $0.033 per remaining share; near the $60,000 cap (Extension contribution calculation) |
The economics of extending are manageable, but the vote’s shareholder base is fragile. If SSEA reverses enough redemptions, the monthly contribution would sit just below the $60,000 cap, so the filing does not reveal a new funding shock. The negative signal is operational: the company must persuade shareholders who already elected redemption to reverse course before it can secure a viable extension process.
Bottom line: This is a delay-and-redemption warning, not progress on the SuperiorMed combination. The extension remains financially feasible, but shareholder support is now the immediate execution risk.
October 19 shareholder meeting
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!